Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study

BACKGROUND: As a potential target receptor tyrosine kinase, mesenchymal-epithelial transition factor (MET) exhibits high aberrant expression across various tumors. This study aimed to evaluated the safety, tolerability, efficacy and pharmacokinetics (PK) of BPI-9016M, a novel tyrosine kinase inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xingsheng, Cui, Xinge, Wang, Ziping, Liu, Yunpeng, Luo, Ying, Zhong, Wei, Zhao, Hui, Yao, Mengxing, Jiang, Da, Wang, Mingxia, Chen, Minjiang, Zheng, Xin, Ding, Lieming, Wang, Yang, Yuan, Xiaobin, Wu, Pengxiang, Hu, Bei, Han, Xiaohong, Shi, Yuankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088252/
https://www.ncbi.nlm.nih.gov/pubmed/37041472
http://dx.doi.org/10.1186/s12885-022-10500-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088252/
https://www.ncbi.nlm.nih.gov/pubmed/37041472
http://dx.doi.org/10.1186/s12885-022-10500-y

Ejemplares similares